Logo

Fresenius Kabi Reports Results of MSB11456 (biosimilar- tocilizumab) in Two Clinical Trials for the Treatment of Rheumatoid Arthritis

Share this
Fresenius Kabi Reports Results of MSB11456 (biosimilar- tocilizumab) in Two Clinical Trials for the Treatment of Rheumatoid Arthritis

Fresenius Kabi Reports Results of MSB11456 (biosimilar- tocilizumab) in Two Clinical Trials for the Treatment of Rheumatoid Arthritis

Shots:

  • The 1st P-I study evaluates MSB11456 as SC formulation vs US-Actemra/EU-RoActemra & 2nd P-I study evaluate MSB11456 vs Actemra as IV formulation in patients with moderately to severely active RA
  • Both studies met all 1EPs & 2EPs i.e.- PK equivalence demonstrated in all 3 treatment groups & no differences in safety and immunogenicity were identified. The first P-I study also showed the similarity b/w MSB11456 & Actemra/RoActemra at PD level
  • The company has completed the patient enrolment in the P-III study of MSB11456 (biosimilar- tocilizumab) vs RoActemra for patients with the same indications across EU

  | Ref: Fresenius Kabi:  | Image:  Fresenius Kabi

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions